GHGuardant Health, Inc.

$170.77

$54.2352 weeks$170.77

Price

$170.77+239%1Y

1M+14%1Y+239%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Top tier

10/10

Value91

Quality45

Momentum88

Growth83

Strongest Value, weakest Quality · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, real-world data and AI analytics. Our tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.

In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$17.47B

1Y Return+239%

5Y Return+52%

Business segments

Q1 2026 · $301.7M

The company’s own SEC segment disclosure.

US$284.6M94%
Non Us$17.0M6%

Guardant Health, Inc. (GH) reported revenue of $335M in Q2 2026 (quarter ended June 30, 2026), up 44% from the same quarter a year earlier. That came with a gross margin of 65% and net loss of $120M. For the full year FY2025, revenue was $982M (+33% year on year) and net income −$416M. Its largest region in 2026-Q1 was US at $285M, 94% of the disclosed total, just ahead of Non Us at 5.6%.

Raw charts

10 series · TTM

As reported to the SEC, without any scoring.

Diagnostics & Research

Ranks #2 of 29 by Smart Score

Medpace Holdings, Inc.